目的 建立阿戈美拉汀藥物利用評(píng)價(jià)標(biāo)準(zhǔn)，評(píng)價(jià)和分析阿戈美拉汀臨床應(yīng)用情況，為臨床合理使用提供參考。方法 以阿戈美拉汀說(shuō)明書(shū)為基礎(chǔ)，參考相關(guān)指南、文獻(xiàn)、診療規(guī)范，建立阿戈美拉汀藥物利用評(píng)價(jià)標(biāo)準(zhǔn)，并以此標(biāo)準(zhǔn)回顧性分析深圳市精神衛(wèi)生中心2022年1月—2025年6月使用阿戈美拉汀的住院患者進(jìn)行用藥合理性評(píng)價(jià)。結(jié)果 共納入280份病歷，用藥適應(yīng)證符合率為86.07%，不合理應(yīng)用常見(jiàn)于用藥療程、特殊人群用藥。結(jié)論 針對(duì)阿戈美拉汀在患者治療過(guò)程中出現(xiàn)的問(wèn)題可作為藥學(xué)部門(mén)積極干預(yù)處理的重點(diǎn)，為進(jìn)一步促進(jìn)臨床合理用藥，保障患者用藥安全提供參考。

Objective To establish the drug use evaluation (DUE) standard for agomelatine in clinical application, and provide reference for its rational use. Methods Based on the drug instructions of agomelatine, relevant guidelines, literatures, diagnosis and treatment standards, the DUE standard was established ,which was used to evaluate the rationality of drug use among inpatients in the Shenzhen Mental Health Center who received agomelatine from January 2022 to June 2025. Results Total 280 inpatients were included, the coincidence rate of medication indication was 86.07%, irrational use of agomelatine was common in course of medication and medication for special populations. Conclusion The problems in the treatment of patients with agomelatine can be regarded as the focus of intervention, and providing a reference for further promoting rational clinical drug use and ensuring the safety of patients’ medications use.

R971

廣東省高水平臨床重點(diǎn)專(zhuān)科（深圳市配套建設(shè)經(jīng)費(fèi)）資助項(xiàng)目（SZGSP013）；深圳市科技創(chuàng)新局項(xiàng)目深圳市精神心理疾病臨床醫(yī)學(xué)研究中心建設(shè)經(jīng)費(fèi)（20210617155253001）